SCHEMBL745140

SCHEMBL745140

Cc1cc(C(N)=O)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3494569 0.98 MAPT (0.53)
SCHEMBL27617928 0.81 MAPT (0.59)
SCHEMBL286771 0.79
SCHEMBL27759338 0.78 RAB9A (0.49)
SCHEMBL11723150 0.78 MAPT (0.61)
SCHEMBL6866293 0.77
SCHEMBL1189897 0.77
SCHEMBL16908080 0.77
SCHEMBL3550338 0.77
Hydrochloric Acid SCHEMBL7095588 0.77 MAPT (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113382990-B Substituted pyrrolidinamide III 格吕伦塔尔有限公司 2024-11-19 CN claimed
CN-118265709-A Tetrahydroisoquinoline compounds as KEAP1 binders 希四克斯探索有限公司 2024-06-28 CN claimed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
EP-3856735-B1 FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS UNIV NEW YORK (US) 2023-09-06 EP claimed
EP-4204393-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2023-07-05 EP claimed
WO-2023057548-A1 CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2023-04-13 WO claimed
WO-2022043374-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2022-03-03 WO claimed
US-9763938-B2 Substituted quinoxalines as positive allosteric modulators of mGluR4 MERCK PATENT GMBH (DE) 2017-09-19 US claimed
EP-2182950-B1 USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS HELPERBY THERAPEUTICS LTD (GB) 2017-07-19 EP claimed
US-20160317533-A1 SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 MERCK PATENT GMBH (DE) 2016-11-03 US claimed
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor YOHANNES DANIEL (US) 2004-06-10 US claimed
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US claimed
EP-1325006-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR NEUROGEN CORPORATION (US) 2003-07-09 EP claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
WO-2003044018-A1 1H-PYRROLO[3,2-B]PYRIDINE-3-CARBOXYLIC ACID AMIDES NEUROGEN CORPORATION (US) 2003-05-30 WO claimed
US-6387934-B1 RHEUMATIC DISEASES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-05-14 US claimed
WO-2002012442-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR NEUROGEN CORPORATION (US) 2002-02-14 WO claimed
CN-1068316-C Process for synthesizing 5-methyl-isoxazole-3-carboxamide KUNSHAN GENERAL PHARMACEUTICAL (CN) 2001-07-11 CN claimed
EP-0829470-B1 2-Cyano-3,5-dihydroxy-hex-2-ene carboxamide derivatives, process for their preparation and their use as medicaments HOECHST AG (DE) 1999-12-15 EP claimed
CN-1156723-A Process for synthesizing 5-methyl-isoxazole-3-carboxamide KUNSHAN GENERAL PHARMACEUTICAL (CN) 1997-08-13 CN claimed